Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (GACD)
HORIZON Research and Innovation Actions
Basic Information
- Identifier
- HORIZON-HLTH-2025-01-DISEASE-06
- Programme
- Cluster 1 - Health (Single stage - 2025)
- Programme Period
- 2021 - 2027
- Status
- Closed (31094503)
- Opening Date
- May 22, 2025
- Deadline
- September 16, 2025
- Deadline Model
- single-stage
- Budget
- €40,000,000
- Min Grant Amount
- €6,000,000
- Max Grant Amount
- €8,000,000
- Expected Number of Grants
- 5
- Keywords
- HORIZON-HLTH-2025-01-DISEASE-06HORIZON-HLTH-2025-01Chronic diseasesClinical managementEmpowermentGlobal healthHealth careHealth care sciences and services (including hospital administration, health care financing)Health inequalitiesHealth management systemsHealth policiesHealth services, health care researchHealthcare systemHomecareIntegrated careMedical servicePatient carePublic healthPublic health policiesQuality of health care
Description
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed, tailored towards and contributing to some of the following expected outcomes:
- Healthcare practitioners and providers in low- and middle-income countries (LMICs)[1] and/or those in high-income countries (HICs) serving disadvantaged populations have access to information allowing to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases (NCDs).
- Public health managers and authorities have access to improved insights and evidence on how to decrease the fragmentation of care for patients living with NCDs and ensure continuity of care across all stages of disease progression, including prevention, risk reduction, and timely diagnosis of NCDs. They use this knowledge to design policies to reduce health inequities and to promote equitable health outcomes.
- Researchers, clinicians and authorities have an improved understanding how the proposed interventions for strengthening health systems for equitable high-quality care and health outcomes in the context of NCDs could be adopted in LMICs and/or disadvantaged populations of HICs setting, taking into account specific social, political, economic and cultural contexts.
- Communities, local stakeholders and authorities are fully engaged in implementing and taking up interventions that strengthen health systems for equitable high-quality care and health outcomes in the context of NCDs and thus contribute to deliver better health, improve quality of life across the life course and extend healthy life expectancy.
The European Commission is a member of the Global Alliance for Chronic Diseases (GACD)[2]. The GACD specifically addresses NCDs and supports implementation science to improve health outcomes. This topic is launched in concertation with the other GACD members (international funding agencies) and aligned with the 10th GACD call.
Health systems in many countries have not kept pace with the rapid emergence of NCDs that require costly long-term care and treatment. Resilient, fit for purpose health system should provide high-quality, safe, equitable, accessible healthcare, that reflects the needs of the population, and enables the integration of healthcare across the care continuum, encompassing prevention, screening, diagnosis and long-term management of NCDs[3]. While health systems across the world struggle with these challenges, this is a particular problem in LMICs that have relatively overburdened, poorly resourced and fragile health systems that struggle to cope with the burden of NCDs. Health inequalities (e.g. linked to geographical location, socioeconomic status, sex and/or gender, ethnicity, disability) are often accentuated by structural and/or systemic weaknesses such as lack of staff and appropriate medicines.
The increasing burden of NCDs on healthcare systems has spurred a greater interest in exploring strategies to tackle these conditions, including a move from a healthcare system focused on disease and hospital-based care, to a more holistic model, involving communities and primary care, and focused on maintaining health[4],[5]. These include interventions addressing the integration of and access to care, screening, access to medicines and technologies, task shifting and digital health interventions. Implementing these strategies while retaining a focus on equity is challenging and health systems need to account for geographical disparities as well as reach communities that have traditionally suffered health inequalities. Equity in health requires that resources and processes are designed to promote equalisation of health outcomes for populations experiencing health disparities, to ensure similar health outcomes for all of society[6].
Evidence for how to strengthen health systems to improve services and ensure equitable health outcomes is emerging, mostly from research in HICs. However, implementing equity-oriented interventions for transformation and/or strengthening of health systems remains challenging and largely unexplored in underserved populations, especially in LMICs. Providing evidence on implementation strategies that can enable effective adaptation and scaling of programmes will be critical to improving survival and quality of life as well as reducing disability, the burden of caretaking on (typically female) family members and costs of healthcare falling on households.
This implementation research topic is therefore focused on strategies to support health system transformation and/or strengthening using evidence-based interventions in the context of NCDs that can be adapted to and implemented in LMICs and/or disadvantaged populations experiencing health disparities in HICs to encourage equitable health outcomes.
The proposed implementation research should be focused on one or more evidence-based interventions (or complex interventions) focused on building equity-orientated health systems change to tackle the growing burden of chronic conditions, including NCDs. The choice of intervention(s) and provision of existing evidence of the intervention’s effectiveness, cost-effectiveness, sustainability, scalability and potential for long-term health and other impacts should be justified (and in what context this evidence has been generated). As the evidence underpinning strategies to transform and/or strengthen health systems in the context of NCDs is still emerging, particularly in LMICs, a limited period of testing the effectiveness of an intervention that the applicant’s team has adapted for local implementation is therefore usually appropriate.
Applicants should explore the implementation of proposed intervention(s) for a selected study population(s) taking into account the unique social, political, economic, and cultural context(s) in which the study will take place. Applicants should justify why any adaptation will not compromise the known effectiveness of the selected intervention(s).
Proposals should address all the following activities[7]:
- Provide a research plan using validated implementation research frameworks or hybrid design research;
- Have an appropriate strategy for measuring implementation research outcomes and real-world effectiveness outcomes and indicators. Other health or non-health outcome measures, especially those identified as important by patient participants and/or critical for advancing Universal Health Coverage (UHC)[8], are also welcome;
- Specifically address health equity and the principles of UHC;
- Engage an appropriately expert and skilled research team which can ensure a suitable multidisciplinary approach and that demonstrates equitable partnership and shared leadership between HIC-LMIC, and/or non-Indigenous-Indigenous members of the project team and external stakeholders through a clear governance strategy;
- Provide a stakeholder engagement strategy with evidence of support/engagement from key stakeholders for delivering patient-centred care;
- Ensure that project partners are engaged from the beginning to contribute to the sustainability of the intervention after the end of project. Proposals should demonstrate sustainability of the strategy, beyond the lifespan of the project;
- Provide opportunities for implementation research capacity building for early career researchers and team members from lower resourced environments, such as LMICs or disadvantaged communities;
- Ensure meaningful involvement of early career team members, including at least one early career member as a co-investigator.
The study population may include the general population, people with one or more existing NCDs, those currently without NCDs, or a combination of both. The study population may also include patients with NCDs and chronic infectious disease(s) (e.g., studies that focus on integrating NCD management into an HIV or tuberculosis clinic). With regard to NCDs, applicants are encouraged to explore any chronic non-communicable condition (or combination of conditions), including mental health disorders, neurological disorders and sleep disorders.
Proposals are expected to use an appropriate implementation research design and frameworks for feasibility studies, cluster randomised control trials (cRCTs), before and after studies, and additional implementation science classifications of study designs (e.g. hybrid designs)[9],[10].
Applicants are not limited to use any particular design, however a validated implementation research framework should underpin the study.
Proposals would be expected to generate evidence that is of direct relevance to policymakers, communities and practitioners. Also, proposals will require a strategy to include the relevant policymakers, local authorities, as well as other stakeholders such as community groups, or other individuals or organisations involved in the implementation of the intervention, with co-creation from the development of the project through to the implementation knowledge translation phase. Applicants should also provide a clear plan for continuing to engage with stakeholders.
Stakeholders also include patients, their family members and carers. Their contributions should be nurtured through meaningful engagement from the outset, not only as participants in the research undertaken. Patient engagement throughout the research project is critical to developing patient-centred models of care.
All stakeholders should be engaged at every stage of the research project, from initial ideation of research questions, throughout the duration of the project, and afterwards during the knowledge translation phase. It is also important to include stakeholders who can help sustain the project’s implementation, facilitate scale up, and use the knowledge generated from the project after the grant ends.
Poverty, racism, gender inequality, ethnic discrimination, and other inequities are directly associated with reduced potential for equitable access to quality care. Proposals should consider the social determinants of health and discuss their potential impact on the effective implementation of the intervention(s). If there is a focus on a particular population (e.g., gender, race and/or ethnicity), then the reason for this should be justified.
In order to promote health equity, proposals should aim to address differences in intervention access, uptake, and effectiveness in socially disadvantaged groups and develop strategies for reducing inequities. To facilitate this process at the data analysis stage, studies should be designed to address such differences. At a minimum, studies should capture and disaggregate data on sex and/or gender differences. If feasible, a plan for capturing intersectional impacts on health outcomes should be included in the analysis strategy.
This topic requires the effective contribution of social sciences and humanities (SSH) disciplines and the involvement of SSH experts, institutions as well as the inclusion of relevant SSH expertise, in order to produce meaningful and significant effects enhancing the societal impact of the related research activities.
All projects funded under this topic are strongly encouraged to participate in networking and joint activities, including internationally, as appropriate. These activities could, for example, involve the participation in joint workshops, the Annual Scientific Meetings of the GACD, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. Therefore, proposals are expected to include a budget for such activities and may consider covering the costs of any other potential joint activities without the prerequisite to detail concrete joint activities at this stage. The details of these joint activities will be defined during the grant agreement preparation phase.
Applicants envisaging to include clinical studies[11] should provide details of their clinical studies in the dedicated annex using the template provided in the submission system.
[1] As defined by the World Bank.
[3] Kruk ME, Pate M, Mullan Z. Introducing The Lancet Global Health Commission on High-Quality Health Systems in the SDG Era. Lancet Glob Health. 2017 May;5(5):e480-e481.
[4] Hunter DJ, Bengoa R, Meeting the challenge of health system transformation in European countries, Policy and Society, Volume 42, Issue 1, March 2023, Pages 14–27.
[5] The WHO has produced a series of recommendations for strengthening health systems, to improve capacity and services to tackle NCDs, with an eye to understanding how the service improvement will be scaled up system-wide; https://apps.who.int/gb/ebwha/pdf_files/WHA66-REC1/A66_R1_ANX4-en.pdf
[6] Health equity is achieved when everyone can attain their full potential for health and wellbeing.
[7] The following types of proposals are not in the scope of this topic: i) proposals with the primary aim of informing the development and/or selection of an intervention for a given context, where the implementation component will be explored in a future project (i.e. standalone feasibility projects);ii) epidemiological cohorts; iii) etiological work, mechanistic, or epidemiological research, unless an essential component of a focused study to develop implementation research approaches; iv) clinical trials, validation studies, or intervention efficacy studies for a new or established pharmacological agent or behavioural intervention.
[8] https://www.who.int/health-topics/universal-health-coverage
[9] Examples of frameworks include (this list is not exclusive): i) Consolidated Framework for Implementation Research (CFIR); ii) the context enhanced (RE-AIM) Reach, Effectiveness, Adoption, Implementation, Maintenance); iii) Practical Robust Implementation and Sustainability Model (PRISM) frameworks.
[10] The following are potential interventions or strategies that applicants may consider in their implementation plan (please note that this is not an exhaustive list): i) Strengthening within the workforce including: training; task shifting within healthcare services; multi-disciplinary teams; community outreach; and the care continuum; ii) Changes in health or related facilities, including relationships, engagement and linkages between facility levels (primary, secondary, tertiary), regional specialist care, pharmacies, and community healthcare; iii) Digital or information technologies in health systems to improve condition management; shared records; coordination in continuum of care; self-management and equitable health outcomes; iv) Implementation of new technologies, innovations for screening, earlier diagnosis and better management of NCDs; v) Ensuring equitable access to good quality medicines (priority medicine lists and financing, monitoring; procurement and distribution; charging and fees); vi) Health policy entrepreneurship linked to solving or capitalizing a policy or practice issues/innovations that have a clear link with service delivery or health promotion with NCDs.
[11] Please note that the definition of clinical studies (see introduction to this work programme part) is broad and it is recommended that you review it thoroughly before submitting your application.
Destination & Scope
Topics under this destination are directed towards the Key Strategic Orientation 3 “A more resilient, competitive, inclusive, and democratic Europe” of Horizon Europe’s strategic plan 2025-2027.
Research and Innovation supported under this destination should contribute to the following expected impact, set out in the strategic plan impact summary for the Health Cluster: “healthcare providers improve their ability to tackle and manage diseases (infectious diseases, including poverty-related and neglected diseases, non-communicable and rare diseases) thereby reducing the disease burden on patients and enabling healthcare systems to perform more effectively. It can be achieved through better understanding, prevention, diagnostics, treatment, management, and cure of diseases and their co- and multi-morbidities, more effective and innovative health technologies and medical countermeasures, better ability and preparedness to manage pandemic and/or epidemic outbreaks, and improved patient safety”.
Communicable and non-communicable diseases cause the greatest amounts of premature death and disabilities and pose a major health, societal and economic threat and burden in the EU and worldwide. Many people are still suffering from these diseases and too often dying prematurely. Although many of these diseases are preventable to a large extend, only around 6% of the healthcare budgets are currently spent on preventive measures[1]. Therefore, there is the urgent need to develop new public health interventions, preventive, diagnostic and therapeutic approaches, alternatives to antimicrobials, as well as to improve existing preparedness and response strategies to create tangible impacts, taking into account sex/gender-related issues. In this regard, Research and Innovation will require international cooperation to pool the best expertise and know-how available worldwide, to access world-class research infrastructures and to leverage critical scales of investments on priority needs through a better alignment with other funders of international cooperation in health Research and Innovation. The continuation of international partnerships and cooperation with international organisations is particularly needed to combat infectious diseases, to address brain health, to respond to public health needs, including the global burden of non-communicable diseases.
In this work programme part, Destination “Tackling diseases and reducing disease burden” will focus on major societal challenges linked to the Commission’s political priorities such as the fight against non-communicable and communicable diseases, mental health and better treatment of mental, behavioural and neurodevelopmental diseases, preparedness and response to and surveillance of health threats and epidemics, reduction and treatment of the number of antimicrobial-resistant infections. In particular, the topics under this destination will support activities aiming at: i) new effective treatment options for patients suffering from antimicrobial resistant (AMR) infections; ii) innovative therapeutic interventions and complementary approaches for patients suffering from mental, behavioural and neurodevelopmental disorders; iii) new prevention and treatment options for infectious diseases with epidemic potential; iv) Artificial Intelligence (AI) based tools and technologies for pandemic preparedness and response; v) implementation research on strengthening health systems in the context of non-communicable diseases; vi) supporting the Global Research Collaboration for Infectious Disease Preparedness; vii) setting up the European Partnership for Brain Health; and viii) supporting efforts of the European Partnership fostering a European Research Area for health research (ERA4Health)[2] in particular in funding large-scale multi-country Investigator-Initiated Clinical Studies (IICS) on various health interventions addressing important public health needs.
In view of increasing the impact of EU investments under Horizon Europe, the European Commission welcomes and supports cooperation between EU-funded projects to enable cross-fertilisation and other synergies. This could range from networking to joint activities such as the participation in joint workshops, the exchange of knowledge, the development and adoption of best practices, or joint communication activities. Opportunities for potential synergies exist between projects funded under the same topic but also between other projects funded under another topic, Cluster or pillar of Horizon Europe (but also with ongoing projects funded under Horizon 2020). In particular, this could involve projects related to European health research infrastructures (under pillar I of Horizon Europe), the EIC strategic challenges on health and EIT-KIC Health (under pillar III of Horizon Europe), or in areas cutting across the health and other Clusters (under pillar II of Horizon Europe). For instance, with Cluster 3 “Civil security for society” such as on health security/emergencies (preparedness and response, medical countermeasures, epidemic outbreaks/pandemics, natural disasters and technological incidents, bioterrorism); with Cluster 4 “Digital, Industry and Space” such as on AI-based tools and technologies (e.g. detection, management and monitoring of an epidemic at population levels, and the diagnosis, treatment, and prevention at the level of individuals); or with Cluster 6 “Food, bioeconomy, natural resources, agriculture and environment” such as on antimicrobial resistance - AMR (e.g. new effective treatment options, alternatives to antibiotics).
Some Research and Innovation actions under this destination should support the mission of the European Health Emergency and Response Authority (HERA) to strengthen Europe’s ability to prevent, detect, and rapidly respond to cross-border health emergencies by ensuring the availability and access to key medical countermeasures. Furthermore, synergies will be sought between this destination and the implementation of the EU4Health Programme (2021-2027)[3]. These synergies and complementarities could be achieved, notably through mechanisms based on feedback loops, enabling on the one hand to identify policy needs that should be prioritised in Research and Innovation actions and facilitating on the other hand the implementation of research results into policy actions and clinical practice, thereby providing an integrated response across sectors and policy fields.
Expected impacts:
Proposals for topics under this destination should set out a credible pathway to contributing to tackling diseases and reducing disease burden, and more specifically to several of the following impacts:
- Disease burden in the EU and worldwide is reduced through effective disease management, including through the development and integration of innovative preventive, diagnostic and therapeutic approaches, digital and other people-centred solutions for healthcare.
- Premature mortality from non-communicable diseases is reduced by one third (by 2030), mental health and wellbeing are promoted, and the voluntary targets of the WHO Global Action Plan for the Prevention and Control of NCDs[4] 2013-2020 are attained (by 2025), with an immediate impact on the related disease burden (Disability-Adjusted Life Years - DALYs)[5],[6],[7].
- Healthcare systems benefit from strengthened Research and Innovation expertise, human capacities and know-how for combatting communicable and non-communicable diseases, including through international cooperation.
- Citizens benefit from reduced (cross-border) health threat of epidemics and AMR pathogens, in the EU and worldwide[8],[9].
- Patients and citizens are knowledgeable of disease threats, involved and empowered to make and shape decisions for their health, and better adhere to knowledge-based disease management strategies and policies (especially for controlling outbreaks and emergencies).
The protection of European communication networks has been identified as an important security interest of the Union and its Member States. Entities that are assessed as high-risk suppliers[10] of mobile network communication equipment (and any entities they own or control) are not eligible to participate as beneficiaries, affiliated entities and associated partners to topics identified as “subject to restrictions for the protection of European communication networks”. Please refer to the Annex B of the General Annexes of this Work Programme for further details.
[1] Preventive healthcare expenditure as a share of the current expenditure on healthcare https://ec.europa.eu/eurostat/statistics-explained/index.php?title=File:Preventive_healthcare_expenditure_as_a_share_of_current_expenditure_on_healthcare,_2021_(%25)_HCE2024.png
[3] https://health.ec.europa.eu/funding/eu4health-programme-2021-2027-vision-healthier-european-union_en
[4] Non-communicable diseases
[5] https://www.who.int/publications/i/item/9789241506236
[6] Including for instance the following voluntary targets (against the 2010 baseline): A 25% relative reduction in the overall mortality from cardiovascular diseases, cancer, diabetes, or chronic respiratory diseases; Halt the rise in diabetes and obesity; An 80% availability of the affordable basic technologies and essential medicines, including generics, required to treat major non-communicable diseases in both public and private facilities.
[7] Disability-adjusted life year (DALY) is a quantitative indicator of overall disease burden, expressed as the number of years lost due to ill-health, disability or early death.
[8] WHO global action plan on antimicrobial resistance, 2015
[9] EU One Health Action Plan against AMR, 2017
[10] Entities assessed as “high-risk suppliers”, are currently set out in the second report on Member States’ progress in implementing the EU toolbox on 5G cybersecurity of 2023 (NIS Cooperation Group, Second report on Member States’ progress in implementing the EU Toolbox on 5G Cybersecurity, June 2023) and the related Communication on the implementation of the 5G cybersecurity toolbox of 2023 (Communication from the Commission: Implementation of the 5G cybersecurity Toolbox, Brussels, 15.6.2023 C(2023) 4049 final).
Eligibility & Conditions
General conditions
1. Admissibility Conditions, Proposal page limit and layout
2. Eligible Countries
Eligible Countries are described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligible Conditions
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
Other Eligible Conditions are described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
Financial and operational capacity and exclusion are described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
Evaluation and award: Award criteria, scoring and thresholds are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold will be 12.
Evaluation and award: Submission and evaluation processes are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
Evaluation and award: Indicative timeline for evaluation and grant agreement are described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
Legal and financial set-up of the grants are described in Annex G of the Work Programme General Annexes.
Specific conditions
Specific conditions are described in the specific topic of the Work Programme.
Application and evaluation forms and additional documents:
Application and evaluation form templates
Standard application form (HE RIA, IA) - the application form specific to this call is available in the Submission System
Standard evaluation form (HE RIA, IA) - will be used with the necessary adaptations
Guidance
Model Grant Agreements (MGA)
Call-specific instructions
Additional documents
HE Main Work Programme 2025 – 1. General Introduction
HE Main Work Programme 2025 – 4. Health
HE Main Work Programme 2025 – 14. General Annexes
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Decision authorising the use of lump sum contributions under the Horizon Europe Programme
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Support & Resources
Online Manual is your guide on the procedures from proposal submission to managing your grant.
Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.
Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues.
CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.
The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.
Partner Search help you find a partner organisation for your proposal.
Latest Updates
Call HORIZON-HLTH-2025-01 closed on 16 September 2025. 749 proposals were submitted. The breakdown per topic is:
- HORIZON-HLTH-2025-01-DISEASE-01: 30 proposals
- HORIZON-HLTH-2025-01-DISEASE-03: 15 proposals
- HORIZON-HLTH-2025-01-DISEASE-04: 76 proposals
- HORIZON-HLTH-2025-01-DISEASE-05: 7 proposals
- HORIZON-HLTH-2025-01-DISEASE-06: 158 proposals
- HORIZON-HLTH-2025-01-DISEASE-07: 83 proposals
- HORIZON-HLTH-2025-01-CARE-01: 118 proposals
- HORIZON-HLTH-2025-01-TOOL-01: 57 proposals
- HORIZON-HLTH-2025-01-TOOL-02: 35 proposals
- HORIZON-HLTH-2025-01-TOOL-03: 82 proposals
- HORIZON-HLTH-2025-01-TOOL-05: 25 proposals
- HORIZON-HLTH-2025-01-IND-01: 58 proposals
- HORIZON-HLTH-2025-01-IND-02: 5 proposals
Evaluation results are expected to be communicated on Wednesday 21 January 2026 at the earliest.
Please note that due to a technical issue, during the first days of publication of this call, the topic page did not display the description of the corresponding destination. This problem is now solved. In addition to the information published in the topic page, you can always find a full description of the relevant destination in the Work Programme 2025 part for "Health". Please select from the work programme the destination relevant to your topic and take into account the description and expected impacts of that destination for the preparation of your proposal.